The PING Innovation Award recognises individuals and organisations whose innovative ideas, products, services or processes in the Pharmaceuticals and Life Sciences sector are making a positive impact on people’s lives. The award is organised by VWV, a leading law firm for the sector.
Mantara’s PGx test is a non-invasive saliva-based test that analyses a person's genetic profile and predicts how they will respond to various medications. The test helps doctors prescribe the right drug at the right dose first time for each patient, reducing the risk of adverse reactions and improving treatment outcomes.
Mantara's Founder, Chair and Medical Director, Dr. Mark Hudson-Peacock, said: "We are honoured and thrilled to receive this prestigious award. It is testament to our team's hard work and dedication to developing innovative solutions that improve patient care and quality of life. We are grateful to VWV, the organisers of the event, and the selection committee for recognising our achievement and potential."
He added: "We would like to thank Paul Gershlick, Head of Pharma & Life Sciences at law firm VWV and Chair of PING, and Paul Witcombe, Life Sciences and Advanced Manufacturing Lead at the Hertfordshire Local Enterprise Partnership, for presenting us the award at the PING Conference 2023."
Paul Gershlick, Chair of PING, Partner and Head of Pharmaceuticals and Life Sciences at the law firm VWV, praised the winner:
"Each year, we have celebrated innovation with this PING Innovation award, and what a worthy winner in Mantara Health. They have the real potential to usher in a new era of personalised treatments, as their ground-breaking pharmacogenomics test will enable individual patients to be treated differently, to obtain the best results for them and make cost savings for the cash strapped NHS. What a fantastic and uplifting way to end this year's PING Conference."
VWV and Mantara congratulate the runners up for their outstanding submissions as well:
Cygenica's GEENIE technology, which provides an innovative helical delivery system of oncology treatments across cell membranes, providing a marked improvement on some current treatments where as little as two to three percent reach the target cells; and
Takeda's white papers and frameworks to increase the availability of combination therapies on the NHS. Currently under half of the licensed combination treatments are available on the NHS, but the frameworks allow value allocation to make them viable on the NHS.
We are proud to be part of such a vibrant and dynamic sector that is driving innovation and excellence in healthcare.
The PING Conference 2023 and award ceremony was held on June 19, 2023, at the grand Old Palace, Hatfield House. The event, “Post Brexit and COVID Life Sciences Challenges: Navigating Stormy Waters”, was attended by approximately 140 industry leaders, experts, and stakeholders to consider and discuss current topics affecting the sector.
For more information about Mantara and its PGx test, please visit https://mantara.co/.
For more information about PING and its events, and a summary of the 2023 conference please follow this link.